Liu, Jian-Qiang; Li, Xue-Feng; Gu, Chu-Ying; da Silva, Julio C. S.; Barros, Amanda L.; Alves, Severino Jr.; Li, Bao-Hong; Ren, Fei; Batten, Stuart R.; Soares, Thereza A. published an article in 2015, the title of the article was A combined experimental and computational study of novel nanocage-based metal-organic frameworks for drug delivery.Quality Control of 5,5′-(Pyridine-2,5-diyl)diisophthalic acid And the article contains the following content:
Three new metal organic frameworks (MOFs) with chem. formulas [(CH3)2NH2] [Sm3(L1)2(HCOO)2(DMF)2(H2O)]·2DMF·18H2O (1), [Cu2(L2)(H2O)2]·2.22DMA (2) and [Zn2(L1)(DMA)]·1.75DMA were synthesized and structurally characterized. 1 and 2 show a classical NbO-like topol. and have two types of interconnected cages. 3 exhibits an uncommon zzz topol. and has two types of interconnected cages. These MOFs can adsorb large amounts of the drug 5-fluorouracil (5-FU) and release it in a progressive way. 5-FU was incorporated into desolvated 1, 2 and 3 with loadings of 0.40, 0.42, and 0.45 g g-1, resp. The drug release rates were 72%, 96% and 79% of the drug after 96 h in 1, 120 h in 2 and 96 h in 3, resp. Grand Canonical Monte Carlo (GCMC) simulations were performed to investigate the mol. interactions during 5-FU adsorption to the three novel materials. The GCMC simulations reproduced the exptl. trend with respect to the drug loading capacity of each material. They also provided a structural description of drug packing within the frameworks, helping to explain the load capacity and controlled release characteristics of the materials. 5-FU binding preferences to 1, 2 and 3 reflect the diversity in pore types, chem. and sizes. The calculated drug load is more related to the mol. properties of accessible volume Vacc than to the pore size. The experimental process involved the reaction of 5,5′-(Pyridine-2,5-diyl)diisophthalic acid(cas: 1431292-15-7).Quality Control of 5,5′-(Pyridine-2,5-diyl)diisophthalic acid
The Article related to nanocage metal organic framework preparation 5fu drug delivery cancer, Pharmaceuticals: Formulation and Compounding and other aspects.Quality Control of 5,5′-(Pyridine-2,5-diyl)diisophthalic acid